Table 1.
Blood–CSF barrier function, CSF and serum albumin, CSF total protein, and CSF L-lactate in group I
| Units | Total | ≤ 14 d | > 14 d | Acute B/SC subgroup | Acute PN/CN/H subgroup | |
|---|---|---|---|---|---|---|
| Blood-CSF barrier function | ||||||
| QAlb > QAlb(lim) | Samples | 58/116 (50%) | 46/82 (56.1%) | 10/21 (47.6%) | 37/65 (56.9%) | 8/16 (50%) |
| QAlb, all LPs | – | 7.9 (1.5–50.8;116) | 8.6 (3.2–50.8;82) | 8.1 (3–14.3;21) | 8.6 (3.3–50.8;65) | 7.7 (3.2–24.8;16) |
| QAlb, if positive | – | 11.4 (6.72–50.8;58) | 11.8 (6.72–50.8;46) | 11.1 (8.09–14.3;10) | 12.9 (6.7–50.8;37) | 11.5 (6.9–24.8;8) |
| Alb CSF | mg/l | 238 (38–1400;116) | 243 (80–1400;82) | 206 (102–516;21) | 240 (106–1400;65) | 276 (80–951;16) |
| Alb serum | g/l | 28.9 (14–54.8;117) | 30.25 (15.4–54.8;82) | 31.9 (14–51.5;21) | 28.3 (15.4–48.4;65) | 36.4 (19.3–54.8;16) |
| Albuminocytological dissociation | Samples | 43/115 (37.4%) | 32/78 (41%) | 7/23 (30.4%) | 37/99 (37.4%) | 6/16 (37.5%) |
| Combined intrathecal synthesis and BCB disruption | Samples | 0/57 (0%) | 0/45 (0%) | 0/10 (0%) | 0/36 (0%) | 0/8 (0%) |
| CSF total protein | ||||||
| CSF TP, elevated | Samples | 54/118 (45.8%) | 41/78 (52.6%) | 8/23 (34.8%) | 35/66 (53%) | 6/11 (54.5%) |
| CSF TP, all LPs | mg/dl | 41.75 (11–240.4;118) | 46.55 (17.5–240.4;78) | 34 (18.7–75.1;23) | 46.55 (17.5–240.4;66) | 48.6 (17.7–158.8;11) |
| CSF TP, if elevated | mg/dl | 65.35 (45.3–240.4;54) | 65.7 (45.3–240.4;41) | 57.6 (45.9–75.1;8) | 70 (45.3–240.4;35) | 63.65 (48.6–158.8;6) |
| CSF TP, > 100 mg/dl | Samples | 12/118 (10.2%) | 10/78 (12.8%) | 0/23 (0%) | 9/66 (13.6%) | 1/11 (9.1%) |
| CSF L-lactate | ||||||
| CSF L-lactate, elevated | Samples | 26/109 (23.9%) | 20/74 (27%) | 3/21 (14.3%) | 17/62 (27.4%) | 2/11 (18.2%) |
| CSF L-lactate, all LPs | mmol/l | 2.1 (1.05–4;109) | 2.1 (1.28–4;74) | 2 (1.05–3.04;21) | 2.1 (1.3–4;62) | 2 (1.28–3.4;11) |
| CSF L-lactate, if elevated | mmol/l | 3.04 (2.2–4;26) | 3.02 (2.2–4;20) | 3.03 (2.79–3.04;3) | 2.25 (1.3–4;33) | 2.2 (1.4–3.4;5) |
| CSF L-lactate, > 3 mmol/l | Samples | 14/109 (12.8%) | 10/74 (13.5%) | 2/21 (9.5%) | 8/62 (12.9%) | 1/11 (9.1%) |
Results are given as medians (with ranges and sample or patient numbers in brackets) and frequencies (with percentages in brackets), respectively. Note that columns 6 and 7 in Tables 1, 2, 3, 4, 5 refer to samples obtained within 14 days after neurological onset (‘acute B/SC subgroup’ and ‘acute PN/CN/H subgroup’, as defined in the Patients section); non-stratified data on the total ‘B/SC subgroup’ and the total ‘PN/CN/H subgroup’ can be found in the Results section and Fig. 1. Alb albumin, BCB bloodCSF barrier, B/SC brain/spinal cord, LP lumbar puncture, PN/CN/H peripheral nerve/cranial nerve/headache only, QAlb CSF/serum albumin ratio, TP total protein.